The Amyloidosis Channel is supported with funding from Prothena (Silver).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy Virtual 2020 | Amyloidosis treatment & response determination
Shaji Kumar, MD, Mayo Clinic, Rochester, MN, discusses amyloidosis treatment and a validated composite organ and hematologic response model for early assessment of treatment outcomes in light-chain amyloidosis. Dr Kumar goes on to discuss the impact of minimal residual negativity (MRD) on outcomes in light-chain amyloidosis. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
